8-K - EHAB - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 14, 2023

Enhabit, Inc.

(Exact name of Registrant as specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-41406	47-2409192
(Commission File Number)	(IRS Employer Identification No.)

6688 N. Central Expressway, Suite 1300, Dallas, Texas 75206

(Address of Principal Executive Offices, Including Zip Code)

(214) 239-6500

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	EHAB	New York Stock Exchange

Item 2.02. Results of Operations and Financial Condition.*

On February 14, 2023, Enhabit, Inc. (the “Company”) issued a press release reporting the financial results of the Company for the quarter and year ended December 31, 2022. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure and Item 7.01.*

A copy of the supplemental information which will be discussed during the Company’s earnings call at 10:00 a.m. Eastern Time on Wednesday, February 15, 2023 is attached to this report as Exhibit 99.2 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press release of Enhabit, Inc., dated February 14, 2023 .*
99.2	Supplemental information provided in connection with the quarter and year ended December 31, 2022 earnings call of Enhabit, Inc.*
104	Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document.

* The information in Item 2.02 and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated into any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified as being incorporated therein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ENHABIT, INC.
By:	/s/ Dylan Black
	Name:	Dylan Black
	Title:	General Counsel

Dated: February 14, 2023

Document

Exhibit 99.1

Enhabit Reports Fourth Quarter Results and Issues Full-Year 2023 Guidance

Company to host a conference call tomorrow, Feb. 15, 2023 at 10 AM EST

DALLAS, TX – Feb. 14, 2022 – Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the fourth quarter ended December 31, 2022.

“Significant changes were required in 2022 to lead important strategies for our future success,” said Enhabit’s President and Chief Executive Officer, Barb Jacobsmeyer. “The expansion of our human resource and talent acquisitions teams, the establishment of our payor innovation team, and strategic changes to management and our staffing model in hospice are all making notable progress. We have also taken steps to align our operational and sales teams into a regional structure to drive success clinically and operationally at a local level. While we face numerous headwinds in 2023, we remain confident in the long-term prospects for Enhabit.”

SUMMARY PERFORMANCE - CONSOLIDATED

•Net service revenue of $275.1 million, declined 0.4% from Q4’21

•Net income of $8.2 million, declined 72.5% from Q4’21

•Adjusted EBITDA of $40.3 million, down 17.8% from Q4’21

•Earnings per diluted share of $0.15

•Adjusted earnings per diluted share of $0.32

RECENT COMPANY HIGHLIGHTS

•Home health continues to have strong growth in Medicare Advantage with nine new negotiated agreements added during the fourth quarter.

•Strategic changes in hospice continue to provide positive momentum with average daily census growing sequentially during the fourth quarter.

•Nursing labor showing signs of improvement with a 19% year-over-year increase in our full-time nursing applicant pool.

•Completed three acquisitions and opened one home health de novo location in the fourth quarter, adding five hospice locations and two home health locations to our portfolio.

FINANCIAL RESULTS

Consolidated

	Q4								'22 vs. '21
($ in millions, except per share data)	2022				2021
Home health net service revenue	$	220.5			$	224.0			(1.6)%
Hospice net service revenue	54.6				52.1				4.8%
Total net service revenue	$	275.1			$	276.1			(0.4)%
	% of Revenue				% of Revenue
Cost of services	48.5%		$	(133.3)	46.5%		$	(128.5)	3.7%
Gross margin	51.5%		141.8		53.5%		147.6		(3.9)%
Administrative & general expenses	37.0%		(101.9)		35.6%		(98.2)		3.8%
Operating expenses	85.5%		$	(235.2)	82.1%		$	(226.7)	3.7%
Equity earnings / noncontrolling interests	0.5				0.4
Adjusted EBITDA	$	40.3			$	49.0			(17.8)%
Adjusted EBITDA margin			14.6%				17.7%
Adjusted EPS	$	0.32			$	0.59			(45.8)%

The continued shift to more non-episodic patients in home health and the resumption of sequestration combined to decrease consolidated revenue approximately $11 million. The impact of these items were offset by an approximate $5 million audit recovery related to a prior year home health medical claims review, improved collections experience related to Medicaid in hospice, and an increase in hospice Medicare reimbursements rates effective October 1, 2022.

Adjusted EBITDA decreased primarily due to the revenue items discussed above, higher cost of services and incremental costs associated with being a stand-alone company. Cost of services were higher due to increased labor costs and costs associated with fleet and mileage reimbursement. Increased labor costs primarily resulted from a $4.3 million increase in employee group medical claims year over year.

SEGMENT RESULTS

Home health

	Q4				'22 vs. '21
($ in millions)	2022		2021
Net service revenue	$	220.5	$	224.0	(1.6)%
Cost of services	109.0		106.4		2.4%
Gross margin	50.6%		52.5%
Adjusted EBITDA	$	51.9	$	59.6	(12.9)%
% Adj. EBITDA margin	23.5%		26.6%
Operational metrics (Actual Amounts)
Starts of care
Episodic admissions	34,572		37,908		(8.8)%
Non-episodic admissions	15,476		12,909		19.9%
Total admissions	50,048		50,817		(1.5)%
Same-store total admissions growth					(3.1)%
Episodic recertifications	25,279		27,273		(7.3)%
Non-episodic recertifications	7,104		5,348		32.8%
Total recertifications	32,383		32,621		(0.7)%
Same-store total recertifications growth					(1.3)%
Total starts of care	82,431		83,438		(1.2)%
Completed episodes	60,250		64,242		(6.2)%
Revenue per episode	$	3,007	$	3,010	(0.1)%
Visits per episode	14.3		15.1		(5.3)%
Total visits	1,159,420		1,219,906		(5.0)%
Non-episodic visits	297,350		246,777		20.5%
Cost per visit	$	92	$	86	7.0%

Total admissions decreased primarily due to a reduction in episodic admissions partially offset by continued growth in non-episodic admissions. Revenue per episode decreased year over year primarily due to the resumption of sequestration and timing of completed episodes partially offset by an increase in Medicare reimbursement rates and an approximate $5 million audit recovery related to a prior year medical claims review.

Adjusted EBITDA decreased year over year primarily due to lower revenue and higher cost of services associated with labor and increased costs associated with fleet and mileage reimbursement. Increased labor costs primarily resulted from a $2.8 million increase in employee group medical claims.

Hospice

	Q4				'22 vs. '21
($ in millions)	2022		2021
Net service revenue	$	54.6	$	52.1	4.8%
Cost of services	24.3		22.1		10.0%
Gross margin	55.5%		57.6%
Adjusted EBITDA	$	12.8	$	15.2	(15.8)%
% Adj. EBITDA margin	23.4%		29.2%
Operational metrics (Actual Amounts)
Total admissions	2,915		3,223		(9.6)%
Same-store total admissions growth					(13.5)%
Patient days	330,102		334,011		(1.2)%
Discharged average length of stay	110		106		3.8%
Average daily census	3,588		3,631		(1.2)%
Revenue per day	$	165	$	156	5.8%
Cost per day	$	74	$	66	12.1%

Revenue per day increased 5.8% year over year primarily due to an increase in Medicare reimbursement rates and improved collections experience related to Medicaid in hospice partially offset by the resumption of sequestration. Average daily census increased sequentially from the third quarter of 2022 primarily due to improvements in staffing capacity.

Adjusted EBITDA decreased year over year primarily due to increased labor costs and costs associated with fleet and mileage reimbursement. Increased labor costs primarily resulted from lower clinical productivity associated with nurses in orientation, increased use of contract labor, and a $0.5 million increase in employee group medical claims.

GUIDANCE

The Company is providing full-year 2023 guidance as follows:

Full-year 2023	Guidance
Net Service Revenue	between $1,110 and $1,140 million
Adjusted EBITDA	between $125 and $140 million
Adjusted EPS	between $0.50 and $0.89

For additional considerations regarding the Company’s 2023 guidance ranges, see the supplemental information provided in the quarterly earnings slide deck posted on the Company’s website at http://investors.ehab.com. See also “Other Information” below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted EPS.

CONFERENCE CALL INFORMATION

The Company will host an investor conference call at 10 AM Eastern Time on Feb. 15, 2023 to discuss its results for the fourth quarter of 2022. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting http://investors.ehab.com. Following the call, a replay will be available at the same location.

ABOUT ENHABIT HOME HEALTH & HOSPICE

Enhabit Home Health & Hospice is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 252 home health locations and 105 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

OTHER INFORMATION

Note regarding presentation of non-GAAP financial measures

The financial data contained in the press release and supplemental information includes non-GAAP financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, leverage ratios, adjusted EPS, and adjusted free cash flow. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP are presented on the attached schedules.

However, in reliance on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K, reconciliation of its guidance of Adjusted EBITDA and adjusted EPS to their corresponding GAAP measures is not provided because the Company is unable to provide such reconciliation, without unreasonable effort, due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Note regarding presentation of same-store comparisons

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

Enhabit, Inc. and Subsidiaries

Condensed Consolidated Statements of Income

(Unaudited)

	Three Months Ended December 31,				For the Year Ended December 31,
	2022		2021		2022		2021
	(In Millions, Except Per Share Data)
Net service revenue	$	275.1	$	276.1	$	1,083.1	$	1,106.6
Cost of service (excluding depreciation and amortization)	133.3		128.5		525.6		513.9
Gross margin	141.8		147.6		557.5		592.7
General and administrative expenses	106.5		103.1		416.9		412.9
Depreciation and amortization	8.3		9.0		33.0		36.9
Operating income	27.0		35.5		107.6		142.9
Interest expense and amortization of debt discounts and fees	8.7		0.1		15.0		0.3
Equity in net income of nonconsolidated affiliates	—		(0.1)		—		(0.6)
Other income	(0.9)		(3.2)		(0.9)		(4.8)
Income before income taxes and noncontrolling interests	19.2		38.7		93.5		148.0
Income tax expense	11.0		8.9		28.9		35.1
Net income	8.2		29.8		64.6		112.9
Less: Net income attributable to noncontrolling interests	0.5		0.5		2.1		1.8
Net income attributable to Enhabit, Inc.	$	7.7	$	29.3	$	62.5	$	111.1
Weighted average common shares outstanding:
Basic	49.6		49.6		49.6		49.6
Diluted	49.8		49.6		49.7		49.6
Earnings per common share:
Basic earnings per share attributable to Enhabit, Inc. common stockholders	$	0.15	$	0.59	$	1.26	$	2.24
Diluted earnings per share attributable to Enhabit, Inc. common stockholders	$	0.15	$	0.59	$	1.26	$	2.24

Enhabit, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

	December 31,<br>2022		December 31,<br>2021
	(In Millions)
Assets
Current assets:
Cash and cash equivalents	$	22.9	$	5.4
Restricted cash	4.3		2.6
Accounts receivable	161.6		164.5
Income tax receivable	9.2		—
Prepaid expenses and other current assets	23.6		6.3
Total current assets	221.6		178.8
Property and equipment, net	20.4		20.4
Operating lease right-of-use assets	42.0		48.4
Goodwill	1,253.8		1,189.0
Intangible assets, net	102.6		259.1
Other long-term assets	5.2		24.3
Total assets	$	1,645.6	$	1,720.0
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt	$	23.1	$	5.0
Current operating lease liabilities	14.0		14.9
Accounts payable	3.8		3.5
Accrued payroll	37.4		66.4
Refunds due patients and other third-party payors	8.3		9.4
Income tax payable	—		4.2
Accrued medical insurance	7.5		8.3
Other current liabilities	40.7		24.8
Total current liabilities	134.8		136.5
Long-term debt, net of current portion	560.0		3.5
Long-term operating lease liabilities	28.1		33.5
Deferred income tax liabilities	42.5		63.2
Other long-term liabilities	1.9		—
	767.3		236.7
Commitments and contingencies
Redeemable noncontrolling interests	5.3		5.0
Stockholders’ equity:
Enhabit, Inc. stockholders’ equity:	844.6		1,470.0
Noncontrolling interests	28.4		8.3
Total stockholders’ equity	873.0		1,478.3
Total liabilities and stockholders’ equity	$	1,645.6	$	1,720.0

Enhabit, Inc. and Subsidiaries

Condensed Consolidated Cash Flows

(Unaudited)

	For the Year Ended December 31,
	2022		2021
	(In Millions)
Cash flows from operating activities:
Net income	$	64.6	$	112.9
Adjustments to reconcile net income to net cash provided by operating activities—
Depreciation and amortization and amortization of debt related costs	33.6		36.9
Equity in net income of nonconsolidated affiliates	—		(0.6)
Distributions from nonconsolidated affiliates	—		0.3
Stock-based compensation	9.2		3.6
Deferred tax expense	9.7		8.6
Other, net	0.1		(5.6)
Changes in assets and liabilities, net of acquisitions—
Accounts receivable	9.5		(24.8)
Prepaid expenses and other assets	(25.3)		(0.1)
Accounts payable	0.2		(0.7)
Accrued payroll	(29.0)		(7.7)
Other liabilities	7.5		0.5
Net cash provided by operating activities	80.1		123.3
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired	(36.3)		(117.5)
Purchases of property and equipment	(7.1)		(4.3)
Other, net	1.1		2.6
Net cash used in investing activities	(42.3)		(119.2)
Cash flows from financing activities:
Principal borrowings on term loan	400.0		—
Principal payments on debt	(10.0)		—
Borrowings on revolving credit facility	190.0		—
Principal payments under finance lease obligations	(5.0)		(7.2)
Debt issuance costs	(4.7)		—
Contributions from Encompass	59.8		126.4
Distributions to Encompass	(654.9)		(154.1)
Contributions from noncontrolling interests of consolidated affiliates	7.4		—
Other	(1.2)		(1.2)
Net cash used in financing activities	(18.6)		(36.1)
Increase (decrease) in cash, cash equivalents, and restricted cash	19.2		(32.0)
Cash, cash equivalents, and restricted cash at beginning of year	8.0		40.0
Cash, cash equivalents, and restricted cash at end of year	$	27.2	$	8.0

Enhabit, Inc. and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	Q4				Full Year
	2022		2021		2022		2021
Earnings per share, as reported	$	0.15	$	0.59	$	1.26	$	2.24
Adjustments, net of tax:
Transaction costs and gain on consolidation	0.05		—		0.14		0.13
Income tax adjustments	0.12		—		0.12		(0.01)
Adjusted earnings per share*	$	0.32	$	0.59	$	1.52	$	2.36

* Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	Q4 QTD
	2022
			Adjustments
	As Reported		Transaction Costs		Income Tax Adjustments		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	40.3	$	—	$	—	$	40.3
Depreciation and amortization	(8.3)		—		—		(8.3)
Interest expense and amortization of debt discounts and fees	(8.7)		—		—		(8.7)
Stock-based compensation	(2.1)		—		—		(2.1)
Transaction costs	(2.5)		2.5		—		—
Income before income tax expense	18.7		2.5		—		21.2
Provision for income tax expense	(11.0)		(0.6)		6.2		(5.4)
Net income attributable to Enhabit	$	7.7	$	1.9	$	6.2	$	15.8
Diluted earnings per share**	$	0.15	$	0.05	$	0.12	$	0.32
Diluted shares used in calculation	49.8

* Reconciliation to GAAP provided on page 15

** Diluted EPS may not sum due to rounding

Enhabit, Inc. and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	Q4 QTD
	2021
			Adjustments
	As Reported		Transaction Costs and Gain on Consolidation		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	49.0	$	—	$	49.0
Depreciation and amortization	(9.0)		—		(9.0)
Interest expense and amortization of debt discounts and fees	(0.1)		—		(0.1)
Gain on disposal or impairment of assets	0.4		—		0.4
Stock-based compensation	(1.5)		—		(1.5)
Stock-based compensation included in overhead allocation	(0.8)		—		(0.8)
Transaction costs	(3.0)		3.0		—
Gain on consolidation of joint venture formerly accounted for under<br> the equity method of accounting	3.2		(3.2)		—
Income before income tax expense	38.2		(0.2)		38.0
Provision for income tax expense	(8.9)		—		(8.9)
Net income attributable to Enhabit	$	29.3	$	(0.2)	$	29.1
Diluted earnings per share**	$	0.59	$	—	$	0.59
Diluted shares used in calculation	49.6

* Reconciliation to GAAP provided on page 15

** Diluted EPS may not sum due to rounding

Enhabit, Inc. and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	Q4 YTD
	2022
			Adjustments
	As Reported		Transaction Costs		Income Tax Adjustments		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	159.3	$	—	$	—	$	159.3
Depreciation and amortization	(33.0)		—		—		(33.0)
Interest expense and amortization of debt discounts and fees	(15.0)		—		—		(15.0)
Loss on disposal or impairment of assets	(0.1)		—		—		(0.1)
Stock-based compensation	(9.2)		—		—		(9.2)
Stock-based compensation included in overhead allocation	(1.1)		—		—		(1.1)
Transaction costs	(9.5)		9.5		—		—
Income before income tax expense	91.4		9.5		—		100.9
Provision for income tax expense	(28.9)		(2.4)		6.2		(25.1)
Net income attributable to Enhabit	$	62.5	$	7.1	$	6.2	$	75.8
Diluted earnings per share**	$	1.26	$	0.14	$	0.12	$	1.52
Diluted shares used in calculation	49.7

* Reconciliation to GAAP provided on page 15

** Diluted EPS may not sum due to rounding

Enhabit, Inc. and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	Q4 YTD
	2021
			Adjustments
	As Reported		Transaction Costs and Gain on Consolidation		Income Tax Adjustments		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	197.2	$	—	$	—	$	197.2
Depreciation and amortization	(36.9)		—		—		(36.9)
Interest expense and amortization of debt discounts and fees	(0.3)		—		—		(0.3)
Gain on disposal or impairment of assets	0.8		—		—		0.8
Stock-based compensation	(3.6)		—		—		(3.6)
Stock-based compensation included in overhead allocation	(2.3)		—		—		(2.3)
Transaction costs	(11.9)		11.9		—		—
Gain on consolidation of joint venture formerly accounted for under<br> the equity method of accounting	3.2		(3.2)		—		—
Income before income tax expense	146.2		8.7		—		154.9
Provision for income tax expense	(35.1)		(2.2)		(0.3)		(37.6)
Net income attributable to Enhabit	$	111.1	$	6.5	$	(0.3)	$	117.3
Diluted earnings per share**	$	2.24	$	0.13	$	(0.01)	$	2.36
Diluted shares used in calculation	49.6

* Reconciliation to GAAP provided on page 15

** Diluted EPS may not sum due to rounding

Enhabit, Inc. and Subsidiaries

Supplemental Information

Reconciliation of Net Income to Adjusted EBITDA

	Three Months Ended<br>December 31,				For the Year Ended<br>December 31,
	2022		2021		2022		2021
	(In Millions)
Net Income	$	8.2	$	29.8	$	64.6	$	112.9
Income tax expense	11.0		8.9		28.9		35.1
Interest expense and amortization of debt discounts and fees	8.7		0.1		15.0		0.3
Depreciation and amortization	8.3		9.0		33.0		36.9
(Gain) loss on disposal or impairment of assets	—		(0.4)		0.1		(0.8)
Stock-based compensation	2.1		1.5		9.2		3.6
Stock-based compensation included in overhead allocation	—		0.8		1.1		2.3
Net income attributable to noncontrolling interests	(0.5)		(0.5)		(2.1)		(1.8)
Transaction costs	2.5		3.0		9.5		11.9
Gain on consolidation of joint venture formerly accounted for under the equity method of accounting	—		(3.2)		—		(3.2)
Adjusted EBITDA	$	40.3	$	49.0	$	159.3	$	197.2

Enhabit, Inc. and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

	Three Months Ended<br>December 31,				For the Year Ended<br>December 31,
	2022		2021		2022		2021
	(In Millions)
Net cash provided by operating activities	$	4.1	$	23.1	$	80.1	$	123.3
Interest expense and amortization of debt discounts and fees	8.7		0.1		15.0		0.3
Equity in net income of nonconsolidated affiliates	—		0.1		—		0.6
Net income attributable to noncontrolling interests in continuing operations	(0.5)		(0.5)		(2.1)		(1.8)
Distributions from nonconsolidated affiliates	—		(0.1)		—		(0.3)
Current portion of income tax expense	(1.2)		1.1		19.2		26.5
Change in assets and liabilities	27.1		21.7		37.1		32.8
Transaction costs	2.5		3.0		9.5		11.9
Stock-based compensation included in overhead allocation	—		0.8		1.1		2.3
Other	(0.4)		(0.3)		(0.6)		1.6
Adjusted EBITDA	$	40.3	$	49.0	$	159.3	$	197.2

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

	Q4				Full Year
($ in millions)	2022		2021		2022		2021
Net cash provided by operating activities	$	4.1	$	23.1	$	80.1	$	123.3
Capital expenditures for maintenance	(1.4)		(0.5)		(4.5)		(5.4)
Distributions paid to noncontrolling interests of consolidated affiliates	(0.3)		(0.2)		(1.2)		(1.8)
Items non-indicative of ongoing operating performance:
Stock-based compensation included in overhead allocation	—		0.8		1.1		2.3
Transaction costs and related assumed liabilities	1.8		6.4		8.8		11.9
Adjusted free cash flow	$	4.2	$	29.6	$	84.3	$	130.3

FORWARD-LOOKING STATEMENTS

Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans, regulatory and other developments impacting the markets for our services, changes in reimbursement rates, general economic conditions, our ability to attract and retain key management personnel and healthcare professionals, potential disruptions or breaches of our or our vendors’ information systems, the outcome of litigation, our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures, and our ability to control costs, particularly labor and employee benefit costs. Our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, each of which will be available on the Company’s website at http://investors.ehab.com and the SEC’s website at www.sec.gov, discuss other risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release. We urge you to consider all of the risks, uncertainties and factors identified above or discussed in such reports carefully in evaluating the forward-looking statements in this press release.

Investor Relations Contact

Mark Brewer

Mark.Brewer@ehab.com

469-860-6061

Media Contact

Erin Volbeda

media@ehab.com

972-338-5141

enhabit_earningsxslidesx

�

� !"#$%&%'

�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̂_5-)+36.-)7&.96*%'.È aZb@53'8'1&7'1&%-,*5&.96*%'.'&1)-)7*0'1*/&1'5&).&.96*%'.41''+&*/43,2D?'+,)+-3-&%-,)*,4%/'*'),);@@=4-)&)+-&3('&*61'*%,%/'(,*%.-1'+%3:+,(0&1&F3'4-)&)+-&3('&*61'*+&3+63&%'.-)&++,1.&)+'2-%/@@=&1'01'*')%'.&%%/'').,4%/-*01'*')%&%-,)DK61L,1(c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

� ! " #$ %& '( )*+ ,-.!! /$ 0 1 '2! 3 +..4 --5,

�

� !"#$"%&$'"##"#() *+,-,./ &)0 )/ &)" *&() ' 1# (1"&1 $$2)"(34 56789: 0 2 5;<8=>$?2#1 $@ABCD><E<;FG' G &H1IC1&H>$'"##"# 6EJ9G#!"% >$'"##"#K<E6<G' G &H1IL'!H 1 $@!"#$ # =EFFG#!"% >0 )&( D&"H/L #2#M N O P-,.# Q2 1"&H"%) &# "&0 )&( $&"H/% #2#RI"S11%&# '&&( ' 1'$ H"#T S"1"(#1&S) %)2"1' 1 5=E<<7G' G &H1I: 0 2 ! )L'!H 1 $@!"#$ 59KG#!"% : 0 2 ! )D&/5J6G' G &H1IL#1! )U"#"1 57;G#!"% L#1! )D&/: %%"H"&1"#1V>>W!)0"$ $!&( #XP1XY Z N[ \ ] O ̂ E N _OEO ̂ 8CI I' I &H1I!&/)'"̀#I"S1&$) #2'!1"S# Q2 #1)&1") $2% $%#H"$&1 $ 1# )0"% ) 0 2 &$>$?2#1 $@ABCD>T/&!!)̀"'&1 H/a++'"H"L#1S# )0"% #"%) &# $!)"'&)"H/$2 1I"(I )%#1#SH&T)b"%) &# $ '!H/ ()2!' $"%&H%H&"'#b&$%#1#&##%"&1 $*"1ISH 1&$'"H &( ) "'T2)# ' 1

�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

�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�RSTUON NVWX Y ZXW[Y
N N
Q N NVZX] Y ]X[Y
̂ !" $.$-#$!"'#!_>>̀ ,*!1$&&!",-J'M:#!Ma

� !" # $ " %&'()*+,-.'/0+.1233(+42.*355(+.4/-20-6789:-2/5;-/:-2/%<-*.-=>'()*+,-.'/0+.1?+/-0@A5,-?-2(*?)BC@A503+4-)D7%A503+4-420-,2.21-,-.*0*2>+.1,56-(E-.->+*+.10*2>/-4/'+*,-.* %F-3(5:+.126+04+3(+.-6233/524?*5,2.21-1/5=*?+.G-6+42/-H6;2.*21-2.64(50-*?-/2*-6+>-/-.*+2(@I2:5/+..5;2*+5.*-2,24*+;-(:-.121-6+.6+04'00+5.0=+*?32:5/02/5'.65'/;2('-3/5350+*+5.%&54'0-65.2/-1+5.2(45.*/24*+.10*/2*-1:%JK3-/+-.4+.10'44-00.-15*+2*+.1-3+056+4/2*-21/--,-.*0=+*?(542(2.6/-1+5.2(32:5/0@<+.-.-=21/--,-.*0.-15*+2*-6+.LD@7M.-=21/--,-.*0+.*5*2(6'/+.10-45.6?2(>5>NCNNO85>7M2/->'(:-K-4'*-6OP5>*?-8-K-4'*-62/-2*-3+056+4/2*-0

�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

� !"#$%&#'(&%)*+!%'%&,-%.&/#0/.!1,$%) 2 3 4 5 !"#$%&#'(&%)*+!%'%&/# 6%),$%) 55 3 4 75829:;<=>;<?;@:AB<?C D879:;<=EFGH@@H:I@ J28KLCMCINCOC?POH@:FC JQ59:;<=B:@;OC?RH@H;8DQ859:;<=RH@H;@58QD9:;<=EFGH@@H:I@ 28D77EMC?<SCT<H=UBCI@N@ JVDLCMCINCOC?T<U JKB:@;OC?T<UEMC?<SCWCIS;X:A>;<UY:;CZ[<?\C;@X<?CH@]<@CF:Î_̂_[CFH̀<?CCaOCIFH;N?C@bW:̀<;H:Ì:NI;H@<@:ATC̀CG]C?cdê_̂ b̂ 5D5D

� !"#!$!%"&'()'*+*',-.,'/.+.0 1211 12134567689:7;6:<6=>?@6=6>6;A6 BCCDEF BCCGED HIEJKL34<M?@6;6:<6=>?@6=6>6;A6 BFGEJ BFCEI GENLO PQ P Q R1STU R1SVU W2UXYZ[\]̂ _̂ à̂ Z[\]̂ _̂ à̂b4<:4c<6=>?@6< defgZ BHIhhEhK difgZ BHICNEFK hEjLkl[mmnolpq̀ grfgZ srdrfe gtfgZ srdufi HhEvKLwx5?;?<:=8:?>6yz6;6=896{M6;<6< tuf|Z BHIDIEvK tgfiZ BHvNECK hENL}M6=8:?;z6{M6;<6< egfgZ BHChFECK e~frZ BHCCJEjK USY}:76=?;@456 BHDEvK BDED€A?:‚?;;6:?;@4564c;4;@4;<49?x8:6x8c?9?8:6< BDED BHDEIKƒ4;@4;:=49?;z?;:6=6<:< BDEF BDEF„… �†‡Oˆ„ R2U R‰U2 WSUŠXY‹/Œ+'/Ž‘’‹#.,“!" ”•– ——–‹/Œ+'/Ž˜™'').$)$.+!%"%"$!/'š."/šš0 R2U1 R2UT‰ WTUŠXY‡PPQ›„… �†‡Oˆ„œ ž›ž P Ÿ ¡8?;4;x?<M4<894c8<<6:< BDED BHDEGK¡8?;4;@4;<49?x8:?4;4c¢4?;:>6;:A=6 BDED BHhECK£:4@¤@45M6;<8:?4;6{M6;<6 BCEI BIEF¥=8;<8@:?4;@4<:<8;x<:4@¤@45M6;<8:?4;6{M6;<6894@8:?4; BCEF BhEN Q ¦¥76@4;:?;A6x<7?c::4;4;§6M?<4x?@M8:?6;:<?;74567689:78;x=6<A5M:?4;4c<6A6<:=8:?4;=6xA@6x=6>6;A68MM=4{?58:69‚BII5?9?4;¦wMM=4{?58:6BF5?9?4;8Ax?:=6@4>6=‚̈?5M=4>6x@496@:?4;<6{M6=?6;@6=698:6x:4©6x?@8?x?;74<M?@68;x8;?;@=68<6?;74<M?@6©6x?@8=6=6?5ªA=<656;:=8:6<4c<6::76x6@9?;6<„… �†‡Oˆ„¦b4;:?;A6x<7?c::454=6;4;§6M?<4x?@M8:?6;:<?;74567689:7̈=6<A5M:?4;4c<6A6<:=8:?4;̈7?z76=98ª4=@4<:<8;x@4<:<8<<4@?8:6x«?:7c966:8;x5?968z6=6?5ªA=<656;:¦¬8ª4=@4<:<?;@=68<6xM=?58=?9‚xA6:48BGEh5?9?4;?;@=68<6?;65M94‚66z=4AM56x?@89@98?5<¦BI5?9?4;?;?;@=656;:89<:8;x§894;6@45M8;‚@4<:<6@4;@?9?8:?4;<:4¡ww®M=4>?x6x4;M8z6<hC:4hN

� !" # $!% & &' () ( ) * +&,- +,& .,/012345364789:;74 <=>?@> <=>A@B C@BDEFGHHIJFKLM NOPQR NSPNRTUV* U�WXYZT +-,[ +-[,/ .,[01R\]̂P_̀ abc\IJFKLM SdPNR SQPQRe ( (.T* T *0( f( gh:43i:;jik:44:3l4 mBnopC mpn?>q rq@qsDt3lu7h:43i:;jik:44:3l4 =onBpA =Cn?>? =?@?DY U -&v&w -&vwx .,-01yjk7u45387535jzjik:44:3l4{83|5} ~dP€Rgh:43i:;87;785:6:;j5:3l4 ConCp? CpnCpm rp@msDt3lu7h:43i:;87;785:6:;j5:3l4 pn=>B onmBq mC@qDY ( (f vw v/ .&,x01yjk7u45387535jz87;785:6:;j5:3l4{83|5} ~Pd€RY ( f( wv wvw .,01‚ U U /&v-& /v ./,01ƒ ) * ( U +v&&x +v&& .&,01„ ( U , -, .-,01Y ) v-[v& v[v[&/ .-,&01t3lu7h:43i:;9:4:54 C?pnmo> CBAnppp C>@oD‚ () +[ +w/ x,&1 ƒ ) * …y583l{{83|5}:ll3lu7h:43i:;jik:44:3l4…y}:6553k387l3lu7h:43i:;hj5:7l54:l}3k7}7jz5}87i†;7i8797l†7jhh83‡:kj57zˆ<Ak:z:3l…‰74†kh5:3l3647Š†7458j5:3l87i†;7i8797l†7jhh83‡:kj57zˆ<Bk:z:3l…‹7i:;jz;zj:k4j†i:587;3978ˆ36jhh83‡:kj57zˆ<ok:z:3l:lŒBC>CCTUV* U�WXYZT…3|788797l†7…Ž:{}78;345364789:;7487zj57i53zj38n6z775jlik:z7j{787:k†847k7l5…j38;3454:l;87j47ih8:kj8:zˆi†753j<C@qk:z:3l:l;87j47:l7khz3ˆ77{83†hk7i:;jz;zj:k4

� !"#$ % %& ' ' ( )*+ )* ,-./01/203456730 89:;< 899;= =>;>?@ABCCDEAFGH IIJIK ILJMKNOP( O�QRSTN ), )* U*,V-KWXYJZ[\]̂ WDEAFGH _̀JaK _bJ_Kcd34e16/fegh314670ij71kegjh/kf10lS O mn* m Un+V-oEDpqCrBAprBrEsEXDGCCGBHCFABtru vẁJIxKy Oz %m% m% UV-T' O ' {z % %+ ,-N ' O z (UNT|V m*,, m+ UV-} ( 'Oz )+* )*+ *,-| 'Oz )~ )++ - } ( €3k3f16egj‚.6f743e03/29;ƒ?24/h„<9>99…353fk3d34†e‡6f743e03†d46he46g‡†k31/ef6f743e036fˆ3†67e43436h‰k403h3f14e130ef†6hd4/53†7/g3716/f03Šd3463f7343ge13†1/ˆ3†67e6†de416eg‡/2031‰‡1‹3430khd16/f/203k3014e16/fNOP( O�QRSTNŒf743e03†7/01/203456730d46he46g‡†k31/6f743e03†ge‰/47/010i6f7gk†6fg/Ž347g6f67egd4/†k716561‡k03/27/f14e71ge‰/4ef†6f743e03†3hdg/‡334/kdh3†67eg7ge6h0lef†6f743e03†7/010e00/76e13†Ž61‹2g331ef†h6g3e3436h‰k403h3f1

� � !"#!$%&#'("%)%*+,'+%-#')(.#)#,'/#01#)*#*%)+2#'3!-#+'3/##0&/4(#*+!&5&!"1#)*'+%!)!$678"%/%!)')(689"%/%!)$!,:;7<77')(7<7=6789"%/%!)')(6>8<"%/%!)%)&!*+*'**!&%'+#(?%+2+2#*+,'+#.%&'/+#,)'+%-#*,#-%#?$!,:;7<77')(7<7=6<8<"%/%!)')(6<8@"%/%!)!$*+!&5&!"1#)*'+%!)%)&/4(#(%)!-#,2#'($!,:;7<77')(7<7='*?#/'*'6<8<"%/%!)')('6>8A"%/%!).'%)!)!+2#,%+#"*$!,:;7<77')(7<7=,#*1#&+%-#/B8 CDEFGEHEIFJK LMNMM O P Q R LMNM O P Q R S � 698T 69T8A S � 678@ 6987 P UR S U V WX 67;8; @8TY 6798@ T8>Y � ZN[\ Z][N^ !"#!$%&#'("%)%*+,'+%-#')(.#)#,'/#01#)*#*(#&,#'*#('*'1#,&#)+'.#!$,#-#)4#1,%"',%/B(4#+!'B#',_!-#,_B#',(#&,#'*#%)&'*2%)&#)+%-#&!"1#)*'+%!)^:;7<77*+')(_'/!)#&!*+*?#,#'11,!0%"'+#/B69"%/%!)=!,')'11,!0%"'+#6"%/%!)%)&,#'*#&!"1',#(+!+2#!-#,2#'('/!&'+%!)$,!"̀)&!"1'** #'/+2%):;7<7 a#&!)&%/%'+%!)*+!bccd1,!-%(#(!)1'.#*>7+!>@

� � � !
"#$%& '() '(* +! "##$%)& '( '(* +!',- $ $ %'& .() /() /,, #0 " 1 - 2 34 # " 3 567898:;<8=><>?@A<?B>CDE>F?;>GHA?;F8;<EB<>;IJK7?;>JHA?;F8;<EB<>;LMN5O7898:;<8=><>?@A<?B>CDE>F?;>GHA?;F8;<EB<>;IOG7?;>JHA?;F8;<EB<>;LPNQ>;D>CA89R?AE>CAF;>?S=EA>SA8?C?D:A>D?;><8FREA?@LMNT:?@EAU89Q?AE>CAV?;>LT8QVNHA?;W?AECBF?F89X?C:?;UPYPG98;S?A>F89F>;ZED>LX:@UYM[PYPY\X:C>GY[PYPMI]R;E@YM[PYPM\̂?;D<GM[PYPPNLPN_8=>_>?@A<V?;>V8CF:=>;]FF>FF=>CA89_>?@A<D?;>Q;8ZES>;FL__V]_QHNQ?AE>CAH:;Z>UHA?;W?AECBF?F89X?C:?;UPYPG98;S?A>F89F>;ZED>LX:@UM[PYPM\X:C>GY[PYPPNLGNW>F>?;D<̀CFAEA:A>98;_8=>V?;>PYPPV<?;Aa88bLS?A?9;8=̂>SED?;>HA?CS?;S]C?@UAEDFcE@>F98;VdPYPMNe_]fg?A?EFVdPYPPL]@R?U8;FN

� !"#$ %&'('')*+,-./01-*/234567898:-2/+:9+8-;.2/*8<=,.898<>?*1/@6@A 3BC6D63E667898:-</279:,-=,.898<>?*1/@6@A 34FADCG8-,-./9/,0/:H98;,<8:-0 35D@I JKL%MN/00OP,0Q,-*.,0Q/R18+,9/-<0 3@@DCS JK(M'S TU �VWIT %MKXI YZ [ \ �VWIT 3B5CD4T[ J]̂MK S _a-78*bc.<:H/2@6@@?d//-</2/*8-<:,3@667898:--:<8:-,9+,91/8-</2/0<2,</0d,e<:Q/*;/<Q/+,28,H9/e:2<8:-:=<Q/2,</:-:12</279:,-DfQ/0d,e=8g/0<Q/hcGi.:7e:-/-<:=:128-</2/0<2,</,<ED4jDfQ/kE@6@@d/8;Q</*,+/2,;/8-</2/0<2,</=:2:12*/H<:1<0<,-*8-;d,05DA5jlhcGim.2/*8<0e2/,*,*n10<7/-<mBA5He0oi/.:-.898,<8:-0<:p))qe2:+8*/*:-e,;/04@<:4F

�

!"#$!" !%&! '() %*+',%-!& '-.#/0!(1 !(.!'+.,%-!#1.#/!2%*+',%34562 )%& '(),!',0 1),' ''#&( ,%/(,,&!%(, 7!1),/),!%(),# '0 !,#-,'0 ! ,(#)-!#13)&#10 ''8 .,9 :;<=><?<@=AB CDDE9F CGHI9JK CDJ9DCGDH9LK CGDH9EK CF9M CEI9N O!#P#!1 2%*9P!Q 'P.#/HFHD 2%*+',%34562 Q '5),!', Q ' R'G),#-!-+)%'K Q )7()S#!T()7Q 0(, . U (),) )&Q 0(, .3R0)%(,+!' 2%*9P!Q 'P.#/HFHHCFCHMCMF CVMCDFF W&#)&(.( ,(#)',#X22O0!#$(%%#)0 7'NH,#NE

� !"#$%#&'&#(!)*(#+*'*, - . /0 / 0 12345672 123224891232:4-; �<=>?- 12@A76 12B@8912:4-; �CD 127@B 147@4891475A EFG9HGIJIK8I9HL89MNNOPQ9RISFS9HPKTFL6B8965

� !"#$%&'() *+*",",-!./*,""#!0.!, ,"12 )134",.)!-#,,"/""5*!")* ,,!4"!,*6!, !"#7',"8' !"#9%:'() *+*",",-!./*,""#!0.!, ,"12 )134"!,** ,,) ; !"#7',"8' < 5"65; !"!,! !!" ,)=,->+ !, )5 ?""/* ;@AB,"A2$/?"C/, ?D*!"# **"D/ ,?;A2,"A9/?"#")"6"?" ,"!C/, ?,!,D*!"#A37/?","A92/?"E D ,"# **"D/ ,?;3F'G?.,)!- ".,"# **"D/ ,?;8$%2/?"!- !

�

!"#$ % & '()*+,-./.)-0(12.,-) 34567 387-93:;'()*+,<92.-(=0(12.,-)>,.-9?/.?@,A) 4467 38-93BC9/D+,E<(0+-(F :;6G 3;-934;H(+,-.,(,<.<(0+-(F.=0.,A+-@/.) :6; 3;-934I

JKLM& JLN JKK O.<9,<+F+(-+9,)-9PQQR0/9S+A.A9,0(E.)85-98T U'()*+,-./.)-0(12.,-)+,5I55+,<F@A.-V9W@(/-./)9?+20(<-?/92A.X-+,<@/.A()0(/-9?-*.).0(/(-+9,?/92Y,<920())Z.(F-*6'()*+,-./.)-0(12.,-)+,5I58/.?F.<-4529,-*)>+,</.().A+,-./.)-/(-.)>(,AF(/E./[\]O)0/.(AA@.-9+,</.().AF.S./(E.6U'()*-(=0(12.,-)+,5I55/.)@F-.A+,(0/.0(12.,-9?(00/9=+2(-.F1372+F+9,()9?̂.<.2X./84>5I556

�

! "# $ "%&# '()*+,-./)(0123-.03340.)5)3 6789 69+)6:;<=2-3-+-).3>7? 6@A8@ B1440C+(0D0EF+-).3>C)()*-.G3?H.0+>9? 6>7I8I? B14>7?J.KL.2L(M7H9I99H*0L<=2-(0DLNIO0=2-+M-.+0(03+P()EQ().+-0(R)E0R0LS+,L.DR)3F-<0HTT/-.LU)-.+50.+2(0*-+,VL-.+;SF,).3233M3+0E*,-<,)F0(L+03,)E0,0LS+,L.D,)3F-<0S)<L+-).3-.1)-30HWDL,)8B,0+)+LSF2(<,L30F(-<0*L367N8XE-S-).L.D*L3P2.D0D).40<0EC0(@7H9I978>9?;E)2.+3-.+,-3()*D).)+-.<S2D0D0C+-.<2(0DL3FL(+)P+,030FL(L+-).+(L.3L<+-).P()EY.<)EFL33R0LS+,8

�

� !"#$%!"# &'#( "!#!"#$)*+ ,,#"# ' - ' "- .*-./$( "!#)/+0123##"!4 &"- ( "!# $&5-$#"# $'' -"# )/+ 6( 6 "!#7"#$6 7"#$ 6( 6 "!#86 9#"# 6( 6 "!#:$!;9#"# )*+<3= (> -?*@/A//%&5 #"! @$#"!!"#$"$> - - $# &>;!"#$"!("-B -)/+C" &$/A/A6( 6 "!#4 &"- - D $5 ,E6 7"#$)*+6( 6 "!#7"#$)*+F "- "! "&$G-D& -3( "!#"$& -D #"##-D #-D& H I J K K L M-D -/A; "-@' ND -D& &"- '#OJPH Q H > ($G"H R 3 "!#;# (@";-"$&# --B%> "-$G $## F -"# $"#$"!;"-?S#"# '#,EIEEET Q

F 3# -"$RJOH H #"#"#-"# G"&D"$#"G $"#-"#$G"$&- #"$$G#"! $#"$&"("$$#->5#-#5-$#$5 &5

� !"##$%&'()!*#+#,()"#!&-$# +#$!&#!,' '..'&+- /0 1 �1 2 3 0 422 52 6 0 1 �137 3 830 9 2 �1 3: 0 9 ;<=>?@ABACDE@>FG?H@E@>H@IE@=>J=>H>?@KLMNCOPQPQ@C@EAR>FGDE=>ICS>I>EA@IHJ>?F TJ>?UQF>?CVCACDE@GC?HJ>=B>E= WF>?@GOBE?F>VEA<E@>CJJC=@<?G@G>H X@=ED@GV>JE=@?>=F<>@CY<EAG@BCOC<@DCS>HZFE@ESE?E[>S>?@DEJE\GAG@G>HZHDEA>E?FSE=]>@F>?HG@B Ĉ@EAR>FGDE=>>?>OGDGE=G>HDICCHG?[R>FGDE=>XFVE?@E[>>_J>D@>F@CDC?@G?<>@C[=C̀ a_JAC=>EFbED>?@V>=@GDEAH@CO<=@I>=\CAH@>=C<=OCC@J=G?@G?ICS>I>EA@IH>=VGD>H

� !"#$%$&'(%)$(*$+,-.$+$,$)/$ 011234 015637 011231 011839 011832 011535 017137 015939 0::539 0:9;37<= < =>"(&'&?#-**-")* 42@28: 89@;79 89@799 47@729 42@:5; 8:@851 42@49: 42@;99 121@894 122@616AB-*"?-.&?#-**-")* 78@4;1 74@8:; 76@526 7:@9;5 7;@92: 7;@4;; 79@64; 82@154 584@576 544@74;C")D$B-*"?-.&?#-**-")* 54@8;6 58@141 57@197 58@77: 51@929 52@:74 52@985 52@4:8 4;@749 84@169>"(&'+$.$+(-E-.&(-")* 71@7:7 71@761 71@882 75@;:; 71@615 71@981 77@;98 75@921 51:@9;1 575@149AB-*"?-.+$.$+(-E-.&(-")* 14@1;9 14@:15 14@997 14@:2: 1;@1;7 1;@;81 1:@196 1:@2:7 521@925 555@798C")D$B-*"?-.+$.$+(-E-.&(-")* ;@528 6@485 6@88; 4@9;9 4@78: 4@122 4@89: 7@:59 16@2;5 59@:64>"(&'*(&+(*"E.&+$ :1@875 :1@525 :5@:79 :4@296 :7@87: :5@748 :8@791 :1@;25 775@86; 775@::4F"#B'$($?$B-*"?$* 62@142 62@796 61@695 67@555 68@181 66@264 6;@:79 66@874 186@88: 168@4:5G,H3+$,$)/$B$+$B-*"?$ 07@22; 07@229 01@9;1 07@27: 07@252 01@956 01@96; 01@917 07@22; 01@948I-*-(*B$+$B-*"?$ 5837 5839 5432 5431 5435 5432 5436 543: 5839 5438>"(&',-*-(* 5@549@812 5@5;4@221 5@15;@88; 5@11:@2:8 5@159@926 5@157@7;2 5@19;@742 5@179@2;7 8@;;9@947 8@969@699C")D$B-*"?-.,-*-(* 19;@742 1;1@1:1 1;4@6;9 1;2@147 186@;;; 112@162 182@226 595@246 5@554@468 :9:@299F"*(B$+,-*-( 091 091 0:: 0:6 0:6 0:; 0:2 0:5 0:9 0:7

� !"#$%&'(')#'*+%&'*'+'(,' -./01 -/20/ -/304 -/20/ -.506 -.504 -.704 -.801 -58605 -582079: 9 :;")<=<>?%##%"(# 5@26. 5@245 5@47. 7@5/1 7@557 7@515 7@524 7@778 66@234 67@667A<)%'()><B# 778@685 758@375 767@364 762@47/ 77/@866 7.5@126 7.6@434 77/@/88 6@54/@741 6@735@248C%#&D<*E'><+'*<E'='(E)D"F#)<B 668 687 682 684 681 681 66. 688 684 683G+'*<E'><%=B&'(#,# 7@.44 7@/41 7@//3 7@../ 7@176 7@47/ 7@413 7@361 7@.62 7@315H'+'(,'$'*><B -61. -6./ -6.5 -6./ -6.1 -6.8 -6.7 -6.6 -6.3 -6.5I"#)$'*><B -3/ -36 -12 -14 -11 -13 -1. -1. -38 -11

� � � � � !" # $%&%$&%$'&%$(&%)*&%$%&$& * &� � +,-./ +01.2 +30.3 +,4.0 +411., +,-.1 +35./ +65.67899:;<8=>8?@?ABC?DEBFG=BHIFCBHJ?99K8?AD> L5./M L3.0M L5.6M L3.3M L10.2M L5.0M L3.1M L2.2MN@@:9DBCOCBHJ8F9?DEBFEFCAP@8@EFB<8=>8?@?ABC?DEBF -.4 -.6 -., -./ 4.3 -., -.0 1.1� � +32.4 +,/.- +35.- +36.- +162.4 +32.- +3-.5 +/2.5 Q8CBFCEAE?DEBF9DBRNNSJ=B<E@8@BFJ?T8954DB5/

� !"# $%&'()'*'+(",-./-010-2"342-54146 789:;<;=>?<@;?A;BCDE;B;C;@F; GHHIJK GHKLJM NIJLOP89AQDE;@;?A;BCDE;B;C;@F; GRSIJR GRSKJM NMJKOP T T U7VWX7 U7V7YXY ZX7[\]̂_̀abacda ]̂_̀abacdae9A?9fA;BCDE;A ghij] GNkRkJlO gmig] GNkIMJKO RJMPnôppqrostc juij] vjjwij jxim] vjyziw {jiy|]}~:D@DA?B=?DC;€;@;B=>;Q;@A;A xmiw] GNMKLJSO xjih] GNMKkJKO SJMP‚Q;B=?D@€;Q;@A;A hjiz] GNKRRJlO hziz] GNKSKJHO 7Xƒ\‚?<;BD@E9:; GNSJKO GNIJlO„…FD?†D@@;?D@E9:;9f@9@E9@A9>D~=?;~=fD>D=?;A G‡ GNSJlOˆ9@E9@?B9>D@€D@?;B;A?A GRJI GIJH‰Š �‹Œ‰ U7ŽXW U7ŽX Z7ŽX[\5‘’"1-5“”•–—)42˜'( $™#š› $š#œ›‰Š �ž%"--/4*/’*41'+("+("*'5-"Ÿ™4(5Ÿ 6 U7X UXWY ZWXY[\ŒT¡‰Š �‹Œ‰V ¢ £¡£ ¤ ¥¦9AAN€=D@O9@~DAQ9A=>9f=AA;?A GSJI GNSJHO§=D@9@E9@A9>D~=?D9@9f̈9D@?C;@?FB; G‡ GNMJRO©?9EªE9:Q;@A=?D9@;Q;@A; GKJR GMJl«B=@A=E?D9@E9A?A=@~A?9EªE9:Q;@A=?D9@;Q;@A;=>9E=?D9@ GISJl GI¬JR ;E9@ED>D=?D9@A?9§}}®QB9CD~;~9@Q=€;AMR?9MH

� !"# $%&'()'*'+(", -. / / 011-2 01324 5-236789:;9<:=>?@A=: BCDED FBGCED GEHIJKLMMNOKPQR STUVW SXUYWZ[\ [�]̂Z 032- 042- 5-267W_̀aUbcdef_NOKPQR XgUSW XSUVWh 5Z Z 6 i jk@:9l@Amln@::@9o: pBDqpCr pDDqCDs trEruIv9ow=k@:9l@Amln@::@9o: DsqCDx BDqGrx GrEsIy9;mzmln@::@9o: {|} {~~ 27mn=w:;9>=;9;mzmln@::@9o:€>9;‚ ƒ„US…Wjk@:9l@A>=A=>;@<@Am;@9o: p†Gqx†p pppqCxB tsEruIv9ow=k@:9l@A>=A=>;@<@Am;@9o: Grq†sp pxqHrD CpEGIy9;mz>=A=>;@<@Am;@9o: -1{3 -4-{} 5-2367mn=w:;9>=;9;mz>=A=>;@<@Am;@9o:€>9;‚ ƒXU‡…Wy9;mz:;m>;:9<Am>= 44-{|~3 44-{11} 52-67ˆ [ [ |~{||1 ~|{}1- 5~267 / [ 04{3 0{}| -217‰ [ -|2 -}2| 54267 / |{33{}4 |{~{~ 542167v9ow=k@:9l@A?@:@;: pqppDqDrB HxHq†xx GBEGIˆ / 01 014 327Š=A9oA@z@m;@9o:;9‹ŒŒk>9?@l=l9okm€=:CG;9CH

� !"#$%&'%(%)&*+ ",

-"! -.! /!.012345364789:;74 <=>?@ <=>?A B>?CDEFGHIIJKGLMN OOPQR OSPTRUVW V�XYU -Z[!\ -[! /"]!.01R̂ _̀Pabcdê JKGLMN QQPfR QSPgRh /U U 0 V ""i.j] "i"" /]!j01klm7n45387535lolpm:44:3q4r83s5t uvOPgwRx Vy "i]Zi]\ "iji.] /![01 V zy "] "j !.1U V y i[". ij\ /![01

Vy -"[j -"[ !1{ Vy -j -\ !"1 |7;3q;:o:l5:3q453}~~€839:p7p3q€lr74C53C‚

� ! "# $%&'&& $%&'& ()&'&& ()&'&*"+,-. -/0123450 67879 :;8<9 6:8<9 :;8=9/0123450>1?4@A4B0 ;C8D9 ;;8E9 ;D8;9 ;<879/4@4B01F450 7869 78G9 7879 C8=9/0123421 ;8E9 ;8D9 ;8E9 ;8D9HAI05 <8;9 <8;9 <8;9 <8E9JKA4L ;<<8<9 ;<<8<9 ;<<8<9 ;<<8<9MKN0M04LAI/0123450 6;869 668;9 6G8:9 6:8E9/0123450>1?4@A4B0 ;=8G9 ;G8:9 ;68G9 ;G8;9/4@4B01F450 68C9 68D9 68D9 78=9/0123421 ;8D9 ;879 ;8D9 ;879HAI05 <8;9 <8;9 <8;9 <8E9JKA4L ;<<8<9 ;<<8<9 ;<<8<9 ;<<8<9OP,Q /0123450 =C8:9 =68C9 =78G9 =68=9/4@4B01F450 G869 ;8=9 G8;9 ;8C9/0123421 <8C9 <879 <879 <879JKA4L ;<<8<9 ;<<8<9 ;<<8<9 ;<<8<9

� � � !"#$"%"&#'()*+),-,).'/0.)0$&1#-'2 3 4 54 6 57 �8659 :; :< :< :;=>?@>ABCDBEFCFGCHE@DBICDBEF JKLMN O O JKLMNPFD>@>QD>R?LCFGCHE@DBICDBEFESG>TDGBQAEUFDQVS>>Q JKLWN O O JKLWNXDEAYAEH?>FQCDBEF>R?>FQ> JZL[N O O JZL[N@CFQCADBEFAEQDQ JZL]N ZL] O O>̂DBFAEH>T>SE@>BFAEH>DCR>Q [KLW ZL] O Z[LZPFAEH>DCRJ>R?>FQ>NT>F>SBD J[[L_N J_L̀N L̀Z J]LaNb 4 � :c;c :d;e :f; :dg;h9 4i 44 j_L[] j_L_] j_L[Z j_LMZ9 4 akLK akLK

� � � !"#$%#&#'$()*+,*-.-*/(01/*1%'2$.(3 4 5 65 7 �896: ;<= ;> ;<=?@AB@CDEFDGHEHIEJGBFDKEFDGH LMNOP Q LMNOPRHF@B@SF@TANEHIEJGBFDKEFDGHGUI@VFIDSCGWHFSXU@@S LONYP Q LONYPZEDHGHIDSAGSE[GBDJAEDBJ@HFGUESS@FS ON\ Q ON\]FGĈCGJA@HSEFDGH@TA@HS@ LYN_P Q LYN_P]FGĈCGJA@HSEFDGHDHC[WI@IDHG̀@Ba@EIE[GCEFDGH LONbP Q LONbPcBEHSECFDGHCGSFS LdNOP dNO QZEDHGHCGHSG[DIEFDGHGUeGDHF̀@HFWB@UGBJ@B[fECCGWHF@IUGBWHI@BFa@@gWDFfJ@FaGIGUECCGWHFDHh dNi LdNiP Qj@FDHCGJ@V@UGB@DHCGJ@FET@S dbNi LONiP dbNORHCGJ@FET@TA@HS@ LbNMP Q LbNMPk 5 � ;<= ;l=m ;<=: 5n 55 oON_M oQ oON_M: 5 \MNp \MNp

� � �!"#$%&$'$(%)*+,-+./.+0)120+2&(3%/)4 5 6 6 7 8 �97 :;<=> :? :? :;<=>@ABCADEFGEHIFIJFKHCGELFGEHI MNNOPQ R R MNNOPQSIGACATGAUBOFIJFKHCGELFGEHIHVJAWGJETDHXIGTYVAAT MZ[OPQ R R MZ[OPQ\HTTHIJETBHTF]HCEKBFECKAIGHVFTTAGT MPOZQ R R MPOZQĜHD_DHKBAITFGEHIAUBAITA M̀OaQ R R M̀OaQĜHD_DHKBAITFGEHIEID]XJAJEIHbACcAFJF]HDFGEHI MZOZQ R R MZOZQdCFITFDGEHIDHTGT M̀O[Q Ò[ R ReAGEIDHKAWAVHCAEIDHKAGFUAT Z̀Of Ò[ R ZPPÒSIDHKAGFUAUBAITA MagÒQ MaOfQ hOa Ma[OZQi 6 � :j>< :k>; :j> :k<>l 6m 66 nZOah nPOZf nPOZa nZO[a 6 f̀Oo f̀Oo

� � ! �"#$%&'%(%)&*+,-.,/0/,1*231,3')4&0*5 6 7 7 8 9 : ! ! ! �;9 <=>? <@ <@ <=>?ABCDBEFGHFIJGJKGLIDHFMGHFIJ NOPQRS T T NOPQRSUJHBDBVHBWCQGJKGLIDHFMGHFIJIXKBYHKFVEIZJHV[XBBV N\QOS T T N\QOS]GFJIJKFVCIVĜIDFLCGFDLBJHIXGVVBHV \Q_ T T \Q_H̀IEaEILCBJVGHFIJBWCBJVB NOQPS T T NOQPSH̀IEaEILCBJVGHFIJFJÊZKBKFJIbBDcBGKĜIEGHFIJ NdQOS T T NdQOSeDGJVGEHFIJEIVHV NffQRS ffQR T T]GFJIJEIJVÎFKGHFIJIXgIFJHbBJHZDBXIDLBD̂hGEEIZJHBKXIDZJKBDHcBBiZFHhLBHcIKIXGEEIZJHFJj OQd NOQdS T TkBHFJEILBYBXIDBFJEILBHGWBV flPQd _Qm T fnlQRUJEILBHGWBWCBJVB NOnQfS NdQdS N\QOS NOmQPSo 7 � <? <p? <q?r <>? 7s 77 tdQdl t\QfO tN\Q\fS tdQOP 7 lRQP lRQP

� � ! "#" " $%&'()'*'+(,- ./.. ./.0 ./.. ./.0 123. 1.432 153 100.346789:;<=>;>?;7@; AABC DBE FDBE GHBA67<;I;@<;>?;7@;=7J=:9I<KL=<K979MJ;N<JK@89O7<@=7JM;;@ DBP CBA AHBC CBGQ;?I;8K=<K97=7J=:9I<KL=<K97 DBG EBC GGBC GRBEST=K7UV9@@97JK@?9@=V9IK:?=KI:;7<9M=@@;<@ W SCBXU CBA SCBDUY<98Z[N=@;J89:?;7@=<K97 FBA ABH EBF GBRY<98Z[N=@;J89:?;7@=<K97K78VOJK7\9];Î;=J=V98=<K97 W CBD ABA FBG_;<K789:;=<IKNO<=NV;<9797897<I9VK7\K7<;I;@<@ SCBHU SCBHU SFBAU SABDUÌ=7@=8<K9789@<@ FBH GBC EBH AABET=K797897@9VKJ=<K979Ma9K7<];7<OI;M9I:;IVb=889O7<;JM9IO7J;I<̂;;cOK<b:;<̂9J9M=889O7<K7\ W SGBFU W SGBFU � 15/3 1543/ 10d43 104e3.

� � !"#$ % &"#'()*+),)-*./ 0100 0102 0100 01023 4 5672 5072 58172 52079:;<=<>;<?@<:><A:BACD=;EFA;ED:DGB<H;BE>IDJ:;>A:BG<<> KLM NLO OPLN NLQRSJE;TE::<;E:IDC<DG:D:ID:>DUEBA;<BAGEUEA;<> V NLO V NLWX<;E:IDC<A;=EHJ;AHU<;D:D:ID:;=DUE:YE:;<=<>;>E:ID:;E:JE:YD@<=A;ED:> ZNLP[ ZNLP[ Z\LO[ ZOLK[]E>;=EHJ;ED:>G=DC:D:ID:>DUEBA;<BAGEUEA;<> V ZNLO[ V ZNLQ[Ĵ=<:;@D=;ED:DGE:IDC<;A?<?@<:>< ZOL\[ OLO O_L\ \WLP^̀ A:Y<E:A>><;>A:BUEAHEUE;E<> \MLO \OLM QMLO Q\LKa=A:>AI;ED:ID>;> \LP QLN _LP OOL_b;DIcdHA><BIDC@<:>A;ED:E:IUJB<BE:De<=̀<ABAUDIA;ED: V NLK OLO \LQf;̀<= ZNLg[ ZNLQ[ ZNLW[ OLW � !"# 5617 56h71 52ih7 52h70

� ! "

" # $� $%�&'($$��%) " !*! +,%-./01/2/3045 6766 6768 6766 6768 9:;8 96;8 97;8 986;<=>?@AB@CDEFGH@>IJHK=ECF@C=CL@ MNOPQ MROSQ MPOSQ MSOPQTE>FHEUGFEJC>B=EDFJCJCLJCFHJVECWECF@H@>F>JILJC>JVED=F@D=IEVE=F@> MROXQ MROYQ MNOYQ MNOZQ( [ )\FJL]̂U=>@DLJKB@C>=FEJCECLVGDECWJ_@H?@=D=VJL=FEJC ` ROZ NON YOXaH=C>=LFEJCLJ>F>=CDH@V=F@D=>>GK@DVE=UEVEFE@> NOZ bOP ZOZ NNOc !

# 9:;6 96d;e 9:; 987;